BOCA RATON, Fla., June 8, 2016 /PRNewswire/ -- Sensus Healthcare,
Inc. (NASDAQ: SRTSU), a medical device company specializing in the
treatment of non-melanoma skin cancers and other skin conditions,
such as keloids, with superficial radiation therapy, today
announced the completion of its initial public offering of
2,300,000 units at a public offering price of $5.50 per unit, before underwriting discounts and
commissions, which includes the exercise in full by the
underwriters of their option to purchase up to 300,000 units at the
initial public offering price. Each unit consists of one share of
common stock, $0.01 par value per
share, and a three-year warrant to purchase one share of common
stock at an initial exercise price of $6.75 per share. All of the units were offered by
Sensus. The units are listed on The NASDAQ Capital Market under the
ticker symbol "SRTSU." Total proceeds to Sensus from the
offering, including proceeds from the option exercise, after
deducting underwriting discounts and commissions and estimated
offering expenses, were approximately $10.9
million.
On or prior to July 25, 2016, each
unit will separate into its components and each such component
security will begin trading separately on The NASDAQ Capital
Market. The common stock is expected to trade under the ticker
symbol "SRTS," while the warrants are expected to trade under the
ticker symbol "SRTSW." Sensus will issue a press release announcing
the date such separate trading will begin.
Northland Securities, Inc., and Neidiger, Tucker, Bruner, Inc.
acted as joint book-running managers for the offering.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
June 2, 2016. The final prospectus
related to the offering may be obtained from Northland Securities
by mail at 750 Third Ave, Suite 2401, New
York, NY 10017, by calling: (800) 851-2920, or by email:
ahammer@northlandcapitalmarkets.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Sensus
Sensus Healthcare, Inc. is a medical
device company that is committed to enabling non-invasive and
cost-effective treatment of non-melanoma skin cancers and keloids.
Sensus uses a proprietary low energy x-ray radiation technology
known as superficial radiation therapy (SRT), which is a result of
over a decade of dedicated research and development activities.
Sensus has successfully incorporated the SRT therapy into its
portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™.
To date, the SRT technology has been used to effectively and safely
treat oncological and non-oncological skin conditions in thousands
of patients. For more information, visit
http://www.sensushealthcare.com.
Investor Relations:
Jeffrey
Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sensus-healthcare-inc-announces-completion-of-initial-public-offering-including-underwriters-exercise-of-over-allotment-option-in-full-300281645.html
SOURCE Sensus Healthcare